Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06862206 | RECRUITING | Chronic Obstructive Pulmonary Disease

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
Sponsor:

AstraZeneca

Brief Summary:

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

Condition or disease

Chronic Obstructive Pulmonary Disease

Intervention/treatment

benralizumab

Study Type : OBSERVATIONAL
Estimated Enrollment : 1000 participants
Official Title : A Multicentre, Single Arm, Non-interventional, Prospective Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
Actual Study Start Date : 2025-07-11
Estimated Primary Completion Date : 2027-12-31
Estimated Study Completion Date : 2027-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply
  • * Patients must to be 12 years old (inclusive) at the time of signing the informed consent.
  • * Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
  • * Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
  • * Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
  • Exclusion criteria
  • -Patients should not enter the study if any of the following exclusion criteria are fulfilled
    • * Patients currently participating in any other clinical trial.
    • * Known history of allergy or reaction to any component of the study treatment formulation.
    • * Malignancy of any kind.
    • * Patients with prior or ongoing treatment with benralizumab.
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Location Details

NCT06862206

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

China,

Research Site

Anhui, China,

RECRUITING

China,

Research Site

Beijing, China,

RECRUITING

China,

Research Site

Binzhou, China,

RECRUITING

China,

Research Site

Guangzhou, China,

RECRUITING

China,

Research Site

Hangzhou, China,

RECRUITING

China,

Research Site

hu Zhou, China,

RECRUITING

China,

Research Site

women, China,

RECRUITING

China,

Research Site

Jinhua, China,

RECRUITING

China,

Research Site

jin ing, China,

RECRUITING

China,

Research Site

Line, China,

RECRUITING

China,

Research Site

Mianyang, China,

RECRUITING

China,

Research Site

Nanchang, China,

RECRUITING

China,

Research Site

Nanjing, China,

RECRUITING

China,

Research Site

Ningbo, China,

RECRUITING

China,

Research Site

Shanghai, China,

RECRUITING

China,

Research Site

Shanxi, China,

RECRUITING

China,

Research Site

S u Ning, China,

RECRUITING

China,

Research Site

Weifang, China,

RECRUITING

China,

Research Site

Xi'an, China,

RECRUITING

China,

Research Site

Zhengzhou, China,